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Summary Enhanced repair of DNA adducts may be a cause of cis-diamminedichloroplatinum(II) resistance
in solid malignancies. Binding of specific damage recognition proteins to the sites of DNA damage may be
involved in the initial steps of DNA repair, or alternatively may block access of repair proteins to damaged
DNA. Proteins which bind specifically to CDDP-modified DNA were identified in cell extracts from human
ovarian carcinoma cell lines by two assays, the gel mobility shift assay and the southwestern blot. In the first
assay, proteins complexed with CDDP-modified oligonucleotide and produced two retarded bands, Bl and B2.
The B2 complex was partially purified from an ovarian cell extract by anion exchange FPLC, and was shown
to bind to DNA damaged by CDDP but not by transDDP or UV irradiation. Using the southwestern blot,
proteins of 97, 48, and 25 kD were identified; each of these bound to CDDP-modified but not undamaged
oligonucleotide. The partially purified B2 protein fraction contained both the 97 and the 25 kD damage
recognition proteins. A human ovarian carcinoma cell line selected in vitro for CDDP-resistance (OVlP/DDP),
which is 5-fold more resistant to CDDP than the parental line (OVIP), showed an increase in binding of the
97 and 48 kD damage recognition proteins compared with the parental line. Twelve ovarian cell lines differed
by up to 3-fold in their expression of these proteins, but there was no correlation between the amount of
damage recognition protein in a cell extract and the cellular sensitivity to CDDP. Damage recognition proteins
were also demonstrated in extracts prepared from biopsies of human ovarian, cervical, and testicular
malignancies, but there was no apparent difference in the binding activity in extracts from tumours of different
CDDP-sensitivity. The functional role of these damage recognition proteins remains to be established.
Chemoresistance to cis-diamminedichloroplatinum(II) (CDDP)
is a major obstacle to the successful treatment of a number
of common solid malignancies, in particular ovarian carcin-
oma. It is widely accepted that CDDP exerts its cytotoxic
effects through covalent binding to DNA to form CDDP-
DNA adducts, which interfere with DNA replication and
transcription (Roberts et al., 1988). The drug binds preferen-
tially to the N7-atoms of guanine (G) and to a lesser extent
to adenine (A), and the most frequent adducts are intra-
strand cross-links between adjacent bases in GG and AG
sequences. It is uncertain which is the most important
mechanism of cellular resistance to this agent but there is
evidence that enhanced repair of CDDP-DNA adducts is an
important factor (Andrews & Howell, 1990). Certain CDDP-
resistant cell lines repair DNA more efficiently than their
sensitive parental lines (Lai et al., 1988; Bedford et al., 1988;
Eastman & Schulte, 1988; Chao et al., 1991a), and there is
some evidence that clinical response to CDDP relates to the
efficiency of DNA repair (Reed et al., 1987; Fichtinger
Schepman et al., 1990).
It has been shown in vitro that Escherichia coli (E. coli)
remove CDDP-DNA adducts by the process of nucleotide
excision repair (Beck et al., 1985). This repair mechanism
removes helix-distortive base damage, such as that produced
by ultraviolet (UV) radiation and bulky chemical adducts. In
E. coli the first step in repair is the recognition of the
damaged DNA by the UvrA2B complex (van Houten, 1990).
Subsequently the bacterial UvrABC nuclease incises the 8th
phosphodiester bond 5' and the 4th phosphodiester bond 3'
to a CDDP-DNA adduct, thereby releasing an oligonucleo-
tide containing the adduct (Beck et al., 1985). CDDP-DNA
adducts can also be repaired in vitro by cell free extracts from
mammalian cells (Hansons & Wood, 1989). Although the
nucleotide excision repair system in eukaryotic cells is in-
completely characterised, mammalian proteins have been
identified which recognise and bind to DNA damaged by
various agents including CDDP (Chu & Chang, 1988; Dona-
hue et al., 1990; Toney et al., 1989; Chao et al., 1991c). It has
been postulated that these damage recognition proteins may
be involved in the initial steps of excision repair, or alterna-
tively may block access of repair enzymes to the sites of
DNA damage. It has been further suggested that these pro-
teins do not recognise specific adducts, but bind to sites
where damage has caused a conformational change in the
DNA (Donahue et al., 1990; Bruhn et al., 1992). An example
of such conformational change may be the 40° bend pro-
duced by an intrastrand crosslink between adjacent guanines
(Rice et al., 1988). Support for the role of damage recogni-
tion proteins in DNA repair has come from the demonstra-
tion that a protein which binds specifically to UV-damaged
DNA can restore the DNA repair capacity of cell extracts
from repair deficient xeroderma pigmentosum cell lines of
complementation group A (Robins et al., 1991).
There is evidence that increased expression of damage
recognition proteins may correlate with CDDP resistance
(CHu & Chang, 1990; Chao et al., 1991c; McLaughlin et al.,
1992). This paper describes the identification of CDDP-
damage recognition proteins in cell extracts from human
tumour cell lines and tumour biopsies using gel-mobility shift
and southwestern blot assays. Correlations between the
CDDP-DNA binding activities of the extracts and the
chemosensitivity of the cell lines and the tissue types of the
tumours are sought.
Materials and methods
Preparation ofoligonucleotide probe
A 54 bp double-stranded oligonucleotide (Oswell DNA,
Edinburgh), was used which has guanine rich sequences
which should serve as preferred sites for formation of
CDDP-DNA adducts; the oligonucleotide sequence was:
GATCCGGGCAACTGATAGGGATTCCCAGATCCGGG-
CAACTGATAGGGATTCCCA
The oligonucleotide was treated, in 10 mM Tris (pH 7.5) and
1 mM EDTA, with CDDP (input drug/nucleotide ratio, 48)
at 37°C for 1 h. Reactions were stopped with 0.1 M
NH4HCO3, and the DNA was recovered by ethanol precipi-
tation, followed by a single wash in 70% ethanol. The CDDP
adducts which resulted from this treatment were identified by
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anion exchange HPLC after enzymatic digestion of the oligo-
nucleotide (Fichtinger-Schepman et al., 1985); platinum
detection was by inductively coupled plasma mass spectro-
metry (Tothill et al., 1990). Of the platinum bound to DNA,
65% was Pt-GG adducts, 10% Pt-AG adducts, and 25%
monofunctional Pt-G adducts. The oligonucleotide was 5'
end labelled with [_y-32P]ATP (5,000 Cimmol-') by T4 poly-
nucleotide kinase in low salt buffer (One-Phor-All Buffer
Plus, Pharmacia), and gel purified. Labelled probe had an
avarage specific activity of 2,000 c.p.m. fmol-' DNA.
Preparation ofwhole cell extracts
The human ovarian tumour cell lines used were A2780 and
A2780/cp7O (Behrens et al., 1987), OVIP and OVIP/DDP
(Bernard et al., 1985; Teyssier et al., 1989), HX/62, SKOV-3,
PXN/94, OVCAR-3, OAW42, OAW28, 59M, PAl, CHI,
41M (Hills et al., 1989), LKI and LK2 (Mistry et al., 1991).
Cells ( '108) were lysed, in a maximum volume of 500f.l,
with Triton X100 (0.25%) in 0.25 M sucrose, 5 mM MgC92,
10 mM Tris (pH 7.5), in the presence of protease inhibitors
(leupeptin 0.1 mg mlh', chymostatin 0.1 mgml1', benzami-
dine 50 mM aprotinin 0.1 mg ml1l, pepstatin 0.1 mg ml-l,
and PMSF 50 mM) at 4°C. Following extraction with 0.3 M
NaCl, the samples were centrifuged (13,000g, 15 min), and
the supernatant was dialysed (Sartorius 12,000 Dalton micro-
collodion tubes) for 16 h against 500 ml storage buffer (SB),
consisting 50 mM (NH3)2 S04, 20 mM HEPES (pH 7.9), 5 mM
MgC92, 0.1 mM EDTA, 1 mM dithiothreitol, and 20% glycer-
ol. Tumour biopsies were stored in liquid nitrogen immed-
iately after surgical removal, and were disaggregated frozen
in a Microdismembrator II (Braun, Germany). Whole cell
extracts were then prepared as above. Protein concentrations
were estimated as described (Bradford, 1976).
Partialpurification ofB2factor
A partially purified protein extract, which bound to CDDP-
treated oligonucleotide, was prepared from a whole cell ex-
tract of the ovarian carcinoma cell line A2780CP by anion
exchange FPLC, using a Mono-Q column (Pharmacia). Ex-
tract protein (5 mg) was loaded on the column in 0.5 ml SB.
The protein fractions eluted in a salt gradient of 0.1 to 1.0 M
NaCl, 20 mM Tris (pH 7.6), and were collected and assayed
for binding activity with CDDP-treated oligonucleotide in
the gel-mobility shift assay.
Gel mobility shift assay
This assay was a modification of the method of Garner and
Revzin (1981). Whole cell extract (1-10gg) was incubated
with 10- 15 fmol of labelled probe, 6jig poly(dI-dC).poly(dI-
dC), and SB buffer to a volume of 20yl for 35 min at 4°C.
The products of the reaction were resolved on an 8% poly-
acrylamide gel; electrophoresis was performed in 0.5% TBE
at 20 mA for 2.5 h at 4'C. Gels were dried and autoradio-
graphed at -70°C overnight; autoradiograph bands were
quantified by scanning laser densitometry.
Modified western blots
This method ofassaying for damage recognition proteins was
a modification of that described (Toney et al., 1989). typic-
ally, 100lg of extract protein was separated by SDS/PAGE
(Laemmli UK, 1970) on a 5-15% gradient gel. Proteins were
transferred from the gel to nitrocellulose membrane by semi-
dry electroblotting. The efficiency of transfer and equal load-
ing of the lanes were confirmed by staining the nitrocellulose
with Ponceau-S stain. Prior to probing the membrane, it was
soaked in 5% dried non-fat milk powder, 50 mM Tris pH 7.5,
50 mM NaCl, 1 mM EDTA, and 1 mM DTT for 1 h, and then
washed briefly in 10mM Tris pH 7.5, 50 mM NaCl, 1 mM
EDTA, and 1 mM DTT. The membrane was then incubated
in 30 mm HEPES-NaOH, pH 7.5, 10 mM MgC92, 2 mM
MnCl2, 0.25% dried non-fat milk powder, with radiolabelled
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Figure 1 Gel mobility shift assay with extract from ovarian line
A2780CP. All lanes 10gg A2780CP extract. Lane 1 unmodified
oligonucleotide, lanes 2-6 CDDP-treated oligonucleotide. Com-
petitor added in lanes 3-6: lane 3 & 4 - 50 & 100 ng unmodified
calf thymus DNA, lanes 5 & 6 - 50 & 100ng CDDP-treated
DNA (input drug: nucleotide ratio 0.08).
oligonucleotide (2 x 104 c.p.m. ml-') and 10 yg ml-' poly(dI-
dC).poly(dI-dC), for 90 min at 20°C. Free oligonucleotide
was removed by washing with 30 mM HEPES-NaOH, pH 7.5,
0.25% dried non-fat milk powder, and the membrane was
dried by air. Protein-oligonucleotide complexes were detected
by autoradiography, and the bands were quantitated by scan-
ning laser densitometry.
Results
Gel mobility shift assay
Following incubation of CDDP-treated oligonucleotide with
extract prepared from the ovarian carcinoma line A2780CP,
two bands of retarded mobility were observed which had
increased affinity compared with unmodified oligonucleotide
(Figure 1). Upon co-incubation with CDDP-treated calf
thymus DNA a dose dependent decrease in the complexes
represented by bands Bi and B2 was observed. These bands
were not competed out by an excess of unmodified DNA
(Figure 1). Both undamaged and CDDP-treated probes were
shifted in the presence of this extract to a number of non-
specific bands. A band was commonly seen above B1 with
CDDP-treated oligonucleotide, but it was not competed out
by CDDP-treated DNA (Figure 1). The presence of non-
specific bands often obscured band B1 and we focused atten-
tion on B2. We have shown that retardation complex Bi is
formed by the binding of the human single-stranded-DNA
binding protein (hSSB) to the CDDP-treated oligonucleotide
(Clugston et al., 1992). The hSSB protein has been shown to
be required for nucleotide excision repair in mammalian cells
(Coverley et al., 1991).744 D. BISSETT et al.
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Figure 2 Gel mobility shift assay with partially purified B2 factor. Extract all lanes 1 p1l of partially purified B2 from
anion-exchange HPLC. Lane 1 unmodified oligonucleotide, lanes 2-14 CDDP-treated oligonucleotide. Competitor added in lanes
3-14: lane 3-5 100 ng, 500 ng,5 pg CDDP-treated calf thymus DNA; lanes 6-8 100 ng, 500 ng, 5plg unmodified DNA; lanes 9- 11
100 ng, 500 ng, 5 pg trans-DDP-treated DNA; lanes 12-14 100 ng, 500 ng, 5 pg uv-irradiated DNA.
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Figure 3 Gel mobility shift assay with extracts from six ovarian carcinoma cell lines. Lanes 1-2 1 p1 partially purified B2, lanes
3-14 10 pg extract. Lanes 3-4 HX/62, lanes 5-6 SKOV-3, lanes 7-8 PXN/94, lanes 9-10 OVCAR-3, lanes 11 -12 CHI, lanes
13-14 41M. Lanes 1, 3, 5, 7, 9, 11, 13 unmodified oligonucleotides; lanes 2, 4, 6, 8, 10, 12, 14 CDDP-treated oligonucleotide.CISPLATIN-DNA DAMAGE RECOGNITION PROTEINS IN HUMAN TUMOUR EXTRACTS
A CDDP-DNA binding protein was partially purified,
from a whole cell extract prepared from the ovarian cell line
A2780CP, by anion exchange FPLC. This extract shifted
CDDP-treated probe only to B2 and served as an internal
standard for the quantification of band B2 in extracts from
other cell lines and tumour biopsies; no shift was seen with
undamaged probe (Figure 2), and the band density of B2 was
linearly related to the amount of protein added to the re-
action (data not shown). Competition experiments were car-
ried out using undamaged and modified calf thymus DNA;
DNA was treated with CDDP or trans-DDP at a drug/
nucleotide ratio of 0.08, or with UV irradiation from a
germicidal lamp with a fluence of 6000 J m 2. A similar
number of DNA lesions should result from each of these
treatments (Patterson & Chu, 1989). The competition experi-
ments showed that binding of the B2 factor to CDDP-
modified oligonucleotide was markedly reduced in the pre-
sence of an excess of CDDP-treated calf thymus DNA, sug-
gesting that binding was both reversible and independent of
nucleotide sequence. The B2 complex bound to CDDP-modi-
fied DNA with at least 100-fold greater affinity than to
undamaged, trans-DDP, or UV-treated DNA (Figure 2).
Figure 3 shows an example of the gel mobility shift assay
for proteins binding to CDDP-treated DNA in six ovarian
carcinoma cell lines. The autoradiography shown has been
overexposed for band B2 to allow visualisation of the other
retardation complexes, however it can be seen that all ex-
tracts retarded the CDDP-treated probe to B2. Crude ex-
tracts prepared from cell lines and subsequently from
tumours showed smearing of the band B2 compared with the
partially purified fraction. This was not improved by altera-
tion of the amount of non-specific competitor poly(dI-dc)
poly (dI-dC) in the reaction. It is possible that this effect was
due to altered binding and dissociation of the B2 complex in
crude extracts due to the presence of other factors. Since our
objective was to examine activity of damage-recognition pro-
teins between cell lines and in tumour biopsies a method of
preparing extracts was used which was rapid and applicable
to tumour biopsies. Therefore the extracts were not routinely
purified or nuclear extracts prepared. Furthermore, purifica-
tion of the binding activity from other factors affecting bind-
ing and dissociation may be less representative of the in vivo
binding activity. The peak areas of the image were compared
with the CDDP IC50 values of the line (Figure 4). No correla-
tion of binding activity of B2 with drug sensitivity were
observed. The binding activities represented by band B2 were
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Figure 4 Relative intensity of band B2 in comparison with
cisplatin IC50 in 12 ovarian carcinoma cell lines. Band intensity
quantified by scanning laser densitometry. Band B2 with I iil
partially purified B2 was assigned standard value 1.0. IC50 values
refer to results of MTT assays with 96 h exposure to CDDP.
examined in extracts from 12 ovarian cell lines and quantified
by laser densitometric scanning where the B2 images did not
saturate detection by autoradiography. Independent mobility
shift assays showed the relative ranking of the activities to be
reproducible. The peak areas of the images were compared
with the CDDP IC50 values of the lines (Figure 4). No cor-
relations of binding activity of B2 with drug sensitivity were
observed. The binding activity of extracts from human
tumour biopsies is shown in Figure 5. Although some differ-
ences were observed between individual tumours no consis-
tent differences were detected between different tumour types.
Modified western blots
Extract proteins (100 jig) from two pairs of CDDP-sensitive
and resistant ovarian carcinoma cell lines (A2780 & A2780CP
and OVIP & OVIP/DDP) were separated on SDS-PAGE
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Figure 5 Relative intensity of band B2 in biopsies of human ovarian, cervical, and testicular tumours.
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and transferred to nitrocellulose. No bands were seen when
the nitrocellulose was probed and unmodified radiolabelled
oligonucleotide (data not shown). Three proteins bound
specifically to CDDP-treated oligonucleotide, and these were
of relative size 97 kD, 48 kD and 25 kD (Figure 6, panel a).
Further proteins of 70 and 23 kD were also seen in some
extracts. The partially purified B2 protein fraction was assay-
ed in this way and was found to contain both the 97 and the
25 kD proteins (data not shown). Although there was no
consistent difference in the binding to these proteins between
extracts from A2780 and A2780CP, there was a difference
between the CDDP-sensitive OV1P and the resistant OVlP/
DDP lines, with an increase in both the 97 kD and 48 kD
bands in the resistant line in separately prepared extracts
(Figure 6, panel a). The modified western blot assay was
applied to the extracts from the other ovarian carcinoma cell
lines and tumour biopsies. The relative binding to each of
these proteins varied between cell lines and tumour types,
and in several extracts only the 25 kDa band was seen
(Figure 6, panel b). There was no correlation between the
intensity of the three bands and the CDDP-sensitivity of the
other 12 ovarian cell lines tested (Figure 7), nor was there
any difference in the proteins between different tumour types
(data not shown).
Discussion
It has previously been shown, using this gel mobility shift
assay, that the binding of UV-DNA and CDDP-DNA
damage recognition proteins is increased in CDDP-resistant
mammalian cells compared with their CDDP-sensitive
counterparts (Chu & Chang, 1990; Chao et al., 1991b,c). In
addition, extracts from a CDDP-sensitive XP-E cell line are
deficient in a factor which binds specifically to UV-modified
oligonucleotide (Chu & Chang, 1988). Using methods which
have already been successful in the identification of these
damage recognition proteins, we sought to demonstrate their
presence in extracts from a panel of human ovarian car-
cinoma cell lines. These lines vary in their inherent sensitivity
to CDDP and may mimic clinical variations in CDDP-
sensitivity more closely than lines which have been rendered
CDDP-resistant by stepwise selection with prolonged expo-
sure to the drug; two examples of such artifically derived
resistant lines were also examined. We have identified
damage-specific DNA binding proteins with a high affinity
for CDDP-treated DNA in all extracts. The protein complex
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represented by band B2 (B2-DRP) bound specifically to
CDDP-modified DNA; and competition experiments, using a
partially purified B2-DRP, showed that it bound with high
affinity to CDDP-treated DNA, irrespective of sequence, but
that it had low affinity for undamaged, trans-DPP-treated,
and UV-irradiated DNA. The binding characteristics of B2-
DRP are thus similar to those described by Donahue et al.
(1990). It is unknown whether damage recognition proteins
bind to the three types of adduct (Pt-GG, PtAG, and Pt-G)
with equal affinity, but this question could be answered by
the synthesis of oligonucleotides containing one specific form
of adduct (Donahue et al., 1990).
Donahue et al. (1990) described a protein with similar
CDDP-DNA binding properties to B2-DRP in the gel mobil-
ity shift assay, and estimated its molecular weight to be
91 kD. The same group have isolated a human cDNA clone
which encodes a CDDP-DNA damage recognition protein;
the predicted size of the protein is at least 81 kD, and it has a
high degree of homology to the high mobility group (HMG)
protein HMG1 (Bruhn et al., 1992). In addition it has been
shown that both HMG-1 and HMG-2 proteins bind specific-
ally to CDDP-modified oligonucleotides, and these proteins
run as a doublet of about 28 kD relative size on a western
blot (Pil & Lippard, 1992). It is highly likely that the damage
recognition proteins described in this paper are the same
HMG proteins, and we have recently shown that the band
B2 can cross-react with antibodies to HMGl (unpublished
data).
There have been reported of increased levels of damage
recognition proteins binding to UV-damaged DNA in CDDP-
resistant cell lines (Chu & Chang, 1990; Chao et al., 1991c)
and of induction of these proteins by exposure to CDDP
(Chao et al., 1991c). However Andrews and Jones (1991)
showed no correlation between the level of CDDP-damage
recognition proteins in ovarian carcinoma cell lines, including
A2780 and A2780CP, and their sensitivity to CDDP. We
have found a similar lack of correlation between CDDP-
sensitivity and the amount of CDDP-DNA binding protein
in a panel of 12 ovarian carcinoma cell lines using both
assays, but in one CDDP-resistant cell line (OVIP/DDP)
there was an increase in two damage recognition proteins
detected by south-western blotting. This may reflect the
deficiences of these two methods as quanitative assays, or
may be due to differences between lines which are inherently
CDDP-resistant and those in which CDDP-resistance is
induced. Using extracts prepared from tumour biopsies, we
have demonstrated damage recognition proteins in ovarian,
b
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Figure 6 Modified western blot ofextract proteins. a, 4 ovarian carcinoma cell lines (100jAg protein per lane). Lane 1, A2780; lane
2, A2780CP; lane 3, OVIP; lane 4, OVIP/DDP. b, Lane 1, HX/62; lane 2, 5 kov-3; lane 3, PXN/94; lane 4, Ovcar-3; lane 5,
OAW42; lane 6, OAW28; lane 7, 59M; lane 8, PA1; lane 9, LK1; lane 10, LK2; lane 11, CH1; lane 12, 41M. Protein sizes are
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Figure 7 Relation of the intensity of 25 kD and 97 kD bands on modified western blot and CDDP IC_% (MTT assays, 96 h
exposure) for 12 ovarian cell lines.
cervical, and testicular malignancies, but there was no appar-
ent difference in the proteins between the different tumour
types.
Although these damage recognition or HMG proteins may
serve a role in the repair of CDDP-DNA adducts, it is
possible that they may have alternative functions such as the
regulation of transcription of damaged DNA or the control
of cell cycling in response to DNA damage. On the other
hand their binding to CDDP-modified DNA may be entirely
fortuitous, in that the alteration of the duplex configuration
induced by a CDDP-DNA adduct may mimic the structure
of the real substrate for these proteins (Lilley, 1992). In this
way HMG protein expression might be induced by CDDP
exposure but have no effect on cellular sensitivity to the drug.
As yet there is much still to be learnt about the function, if
any, of these damage recognition proteins in DNA repair.
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